Cihlarova Hana, Bencova Lenka, Zlatohlavkova Blanka, Allegaert Karel, Pokorna Pavla
Division of Neonatology, Clinic of Gynaecology and Obstetrics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia.
Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia.
Front Pediatr. 2022 Jun 23;10:895040. doi: 10.3389/fped.2022.895040. eCollection 2022.
Intravenous paracetamol added to morphine reduces postoperative morphine consumption in (near)term neonates. However, there are only sparse data on intravenous paracetamol as multimodal strategy in extremely low birth weight (ELBW) neonates.
This study aims to assess the effects of rescue intravenous paracetamol on postoperative pain management (≤48 h postoperatively) in relation to both analgesic efficacy (validated pain assessment, drug consumption, adequate rescue medication) and safety (hypotension and bradycardia). This rescue practice was part of a standardized pain management approach in a single neonatal intensive care unit (NICU).
A single-center retrospective observational study included 20 ELBW neonates, who underwent major abdominal surgery. The primary endpoints of the postoperative study period were pain intensity, over-sedation, time to first rescue analgesic dose, and the effect of paracetamol on opiate consumption. Secondary endpoints were safety parameters (hypotension, bradycardia). And as tertiary endpoints, the determinants of long-term outcome were evaluated (i.e., duration of mechanical ventilation, intraventricular hemorrhage - IVH, periventricular leukomalacia - PVL, postnatal growth restriction, stage of chronic lung disease - CLD or neurodevelopmental outcome according to Bayley-II Scales of Infant Development at 18-24 months).
All neonates received continuous opioids (sufentanil or morphine) and 13/20 also intravenous paracetamol as rescue pain medication during a 48-h postoperative period. Although opioid consumption was equal in the non-paracetamol and the paracetamol group over 48 h, the non-paracetamol group was characterized by oversedation (COMFORTneo < 9), a higher incidence of severe hypotension, and younger postnatal age ( < 0.05). All long-term outcome findings were similar between both groups.
Our study focused on postoperative pain management in ELBW neonates, and showed that intravenous paracetamol seems to be safe. Prospective validation of dosage regimens of analgesic drugs is needed to achieve efficacy goals.
对(近)足月新生儿,静脉注射对乙酰氨基酚联合吗啡可减少术后吗啡用量。然而,关于静脉注射对乙酰氨基酚作为极低出生体重(ELBW)新生儿多模式镇痛策略的数据非常有限。
本研究旨在评估补救性静脉注射对乙酰氨基酚对术后疼痛管理(术后≤48小时)的影响,涉及镇痛效果(经过验证的疼痛评估、药物消耗、足够的补救药物)和安全性(低血压和心动过缓)。这种补救措施是单一新生儿重症监护病房(NICU)标准化疼痛管理方法的一部分。
一项单中心回顾性观察研究纳入了20例接受大型腹部手术的ELBW新生儿。术后研究期的主要终点是疼痛强度、过度镇静、首次使用补救性镇痛药物的时间,以及对乙酰氨基酚对阿片类药物消耗的影响。次要终点是安全性参数(低血压、心动过缓)。作为三级终点,评估长期预后的决定因素(即机械通气持续时间、脑室内出血-IVH、脑室周围白质软化-PVL、出生后生长受限、慢性肺病-CLD分期或18-24个月时根据贝利婴幼儿发育量表II评估的神经发育结局)。
所有新生儿在术后48小时内均接受持续阿片类药物(舒芬太尼或吗啡)治疗,20例中有13例还接受静脉注射对乙酰氨基酚作为补救性镇痛药物。尽管48小时内非对乙酰氨基酚组和对乙酰氨基酚组的阿片类药物消耗量相同,但非对乙酰氨基酚组的特点是过度镇静(COMFORTneo<9)、严重低血压发生率较高且出生后年龄较小(P<0.05)。两组的所有长期预后结果相似。
我们的研究聚焦于ELBW新生儿的术后疼痛管理,结果显示静脉注射对乙酰氨基酚似乎是安全的。需要对镇痛药物的剂量方案进行前瞻性验证以实现疗效目标。